UroGen Expands Oncology Pipeline Through IntraGel Deal
PRINCETON, New Jersey, August 20, 2026 UroGen Pharma Ltd. announced a strategic collaboration and investment agreement with IntraGel Therapeutics,...
Head and Neck Cancer
Advertisement
Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Corbus Moves CRB-701 Toward FDA Registration
NORWOOD, Mass., July 28, 2026 Corbus Pharmaceuticals Holdings, Inc. has received U.S. Food and Drug Administration (FDA) clearance to...
Advertisements
MacroGenics Reports Positive Phase 1 MGC026 Cancer Study Update
ROCKVILLE, MD, July 23, 2026 MacroGenics, Inc. announced a significant clinical update from its ongoing Phase 1 study of...
Alpha Tau Medical Ltd. Reports Positive Head and Neck Cancer Results
JERUSALEM, July 21, 2026 Alpha Tau Medical Ltd. announced positive clinical study results evaluating its Alpha DaRT® (Diffusing Alpha-emitters...
Inhibrx Reports Progress for INBRX-106 in HNSCC Trial
SAN DIEGO – May 8, 2026 Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...
Spago Nanomedical Advances Tumorad-01 With MTD Milestone
STOCKHOLM, Sweden – May 6, 2026 Spago Nanomedical AB (publ) has announced that its ongoing Phase I/IIa Tumorad-01 study...
Alpha Tau Medical Ltd. Showcases Alpha DaRT Data
JERUSALEM, Israel – May 5, 2026 Alpha Tau Medical Ltd. has announced that new clinical data evaluating Alpha DaRT®...
Advertisement
